Bellerophon Therapeutics, Inc. (BLPH) Financial Statements (2024 and earlier)

Company Profile

Business Address 184 LIBERTY CORNER ROAD, SUITE 302
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10,57515,1726,92411,31716,32820,000
Cash and cash equivalents10,57515,1726,92411,31716,32820,000
Restricted cash and investments107405405404403103
Other undisclosed current assets563194234338257413
Total current assets:11,24515,7717,56312,05916,98820,516
Noncurrent Assets
Operating lease, right-of-use asset  8184357529697
Property, plant and equipment  1262746
Restricted cash and investments      300
Other noncurrent assets  186186186186186
Total noncurrent assets:  1953725497421,229
TOTAL ASSETS:11,24515,9667,93512,60817,73021,745
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,2312,4982,5432,8953,3512,944
Accounts payable1,8871,0701,2301,5252,0072,193
Accrued liabilities1,3441,4281,3131,3701,344751
Other undisclosed current liabilities2,391 2,8582,2842,0982,622
Total current liabilities:5,6222,4985,4015,1795,4495,566
Noncurrent Liabilities
Long-term debt and lease obligation:      8
Operating lease, liability      8
Other undisclosed noncurrent liabilities    11(7)
Total noncurrent liabilities:    119
Other undisclosed liabilities  2,866    
Total liabilities:5,6225,3645,4015,1805,4505,575
Equity
Equity, attributable to parent5,62310,6022,5347,42812,28016,170
Common stock12210496959595
Additional paid in capital259,895259,754254,516254,395254,178253,963
Accumulated deficit(254,394)(249,256)(252,078)(247,062)(241,993)(237,888)
Total equity:5,62310,6022,5347,42812,28016,170
TOTAL LIABILITIES AND EQUITY:11,24515,9667,93512,60817,73021,745

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues  5,640    
Gross profit:  5,640    
Operating expenses(5,259)(4,161)(5,085)(5,116)(6,541)(5,642)
Operating income (loss):(5,259)1,479(5,085)(5,116)(6,541)(5,642)
Nonoperating income121 6847191
Income (loss) from continuing operations before equity method investments, income taxes:(5,138)1,479(5,017)(5,069)(6,522)(5,641)
Other undisclosed income from continuing operations before income taxes 661   
Income (loss) from continuing operations before income taxes:(5,138)1,545(5,016)(5,069)(6,522)(5,641)
Income tax benefit  1,277  2,417 
Income (loss) from continuing operations:(5,138)2,822(5,016)(5,069)(4,105)(5,641)
Loss before gain (loss) on sale of properties:(5,069)(4,105)(5,641)
Net income (loss) available to common stockholders, diluted:(5,138)2,822(5,016)(5,069)(4,105)(5,641)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(5,138)2,822(5,016)(5,069)(4,105)(5,641)
Comprehensive income (loss), net of tax, attributable to parent:(5,138)2,822(5,016)(5,069)(4,105)(5,641)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: